United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Paycom Software

T-Mobile US

Wells Fargo

Here's the latest activity in Berkshire's portfolio, plus other top financial news.

What Warren Buffett Has Been Buying and Selling

Conagra Brands

Cardinal Health

Kellogg

Kimberly-Clark

Lockheed Martin

Philip Morris

Which dividend stocks should you consider for both 3%+ yields and the potential for appreciation? These nine names come to mind.

9 Great Dividend Stocks with 3%+ Yields

Pacific Biosciences of California

Moderna

The battle against Covid-19 is about to get uglier. Coronavirus mutations threaten to undercut a year's worth of work upholding Covid stocks like Pfizer, Moderna and Regeneron Pharmaceuticals.

Coronavirus Mutations: Why The Battle Against Covid Is Just Beginning

The European Medicines Agency has accepted for review Pfizer Inc's (NYSE: PFE) marketing application seeking approval for the 20-valent pneumococcal conjugate vaccine (20vPnC). The vaccine candidate is for preventing invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes in adults ages 18 years and older.

Pfizer's 20-Valent Pneumococcal Vaccine Application Accepted EU Review

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the European Medicines Agency (EMA) accepted for review the Marketing Authorization Application (MAA) for its 20-valent pneumococcal conjugate vaccine (20vPnC) candidate, as submitted for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes in the vaccine in adults ages 18 years and older. With the MAA acceptance, the formal review process by the EMA's Committee for Medicinal Products

European Medicines Agency Accepts Pfizer's Marketing Authorization Application for Its Investigational 20-valent Pneumococcal Conjugate Vaccine for Adults 18 Years of Age or Older

BioNTech SE

A single dose of the COVID-19 vaccine made by Pfizer and BioNTech reduces infections and lowers the risk of transmission, according to a new study.

Pfizer vaccine can reduce transmission after 1 dose, new study finds

OPKO Health

NEW YORK & MIAMI--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the European Medicines Agency (EMA) has validated for review the Marketing Authorization Application (MAA) for somatrogon, a long-acting recombinant human growth hormone that is intended to be administered once-weekly for the treatment of pediatric patients with growth hormone deficiency (GHD). Pfizer expects a decision from the European Commission in 2022. “Today's announcement is

EMA Accepts Marketing Application for Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency

Barrick Gold

SNDL Inc.

These widely held stocks were on the chopping block during the fourth quarter.

3 Popular Stocks Billionaires Can't Stop Selling

Your free daily email from Fuller Treacy Money Comments of the Day 26 February 2021   Video commentary for February 25th 2021   Eoin Treacy's view A link to today's video commentary is posted in the Subscriber's Area.  Some of the topics discussed include: Treasury yields spike higher, stcocks and bonds pause, oil eases, gold weak, bitcoin steady yield curve steepening.

"Real world" test of Pfizer COVID-19 vaccine in Israel determines effectiveness in preventing illness

This change could make handling the vaccine easier for small clinics with few resources.

Pfizer's Covid Vaccine Doesn't Need Ultra-Cold Storage, FDA Says

Franklin Resources

Edison

Enbridge

Lazard

Magellan Midstream Partners

Altria

OGE Energy

ONEOK

Prudential Financial

Valero Energy

This monthly series ranks a selection of dividend growth stocks in Dividend Radar, presenting the 10 top-ranked stocks for consideration.

10 Dividend Growth Stocks For February 2021

Implied Volatility in the 3rd percentile is at the same level as it was before the Covid-19 vaccine. Volatility spikes driven by news aren't priced in. Options volatility is also skewed negative and pricing in a $0.10 drop. Historically, this marks great buying opportunities as investors are over bearish.

Forget Pfizer Stock, Buy Historically Cheap Call Options

Apple

Alibaba

Borr Drilling Ltd

Chevron

Freeport-McMoRan

AT&T

These cheap stocks are ready to rally as markets look for value. Each is fundamentally strong for a near-term trade and long-term investment.

7 Cheap Stocks to Buy for March

Pfizer is exploring two paths with its vaccine to try providing more protection against new Covid strains, according to board member Dr. Scott Gottlieb.

Pfizer director Dr. Scott Gottlieb explains how a third Covid shot may protect against variants

Johnson & Johnson

Coca-Cola

Walmart

These 5 stocks are great stocks to buy in any future market crash, as they all have good fundamentals and great long-term prospects. The post 5 Surefire Stocks If the Market Crashes appeared first on InvestorPlace.

5 Surefire Stocks If the Market Crashes

Moderna, Inc. (NASDAQ:MRNA) said it expects to make US$18.4bn (£13bn) in revenue this year as governments worldwide have booked millions of doses of its COVID-19 vaccine. In 2020, total revenue rocketed 93% to US$803mln, mostly due to grants by the US government to speed up the development of the jab.

Coronavirus: Moderna forecasts US$18.4bn sales this year, Pfizer/BioNTech vaccine proved highly effective by study on 1.2mln people

Pfizer Inc. and BioNTech SE said Thursday they have initiated the evaluation of a third dose of their COVID-19 vaccine, to study the effect of a booster on new SARS-CoV-2 variants. The study will draw on participants of its Phase 1 study in the U.S., who will be offered the opportunity to receive a booster of the current vaccine six to 12 months after receiving their initial two doses.

Pfizer, BioNTech to test a COVID-19 vaccine booster against new SARS-CoV-2 variants

A real-world study of the coronavirus vaccine developed by Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) showed the drug to be 94 percent effective at preventing COVID-19. What Happened: The large-scale study conducted in Israel found the two-dose vaccine reduced symptomatic cases by 94 percent one week after the second dose and also reduced the severity of the disease by 92 percent, Nikkei Asia reported on Thursday.

Pfizer-BioNTech Vaccine 94% Effective In Real World: Study

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today they have begun an evaluation of the safety and immunogenicity of a third dose of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) to understand the effect of a booster on immunity against COVID-19 caused by the circulating and potential newly emerging SARS-CoV-2 variants. The study will draw upon participants from the Phase 1 study in the United States who will be offered the oppor

Pfizer and BioNTech Initiate a Study as Part of Broad Development Plan to Evaluate COVID-19 Booster and New Vaccine Variants

The FDA has signaled an eagerness in recent days for progress on vaccines that can offer protection from the emerging variants.

Pfizer Will Test Third Dose of Vaccine to Protect Against Variants

Pfizer and BioNTech announced this morning that they plan to study the effects of a third COVID-19 vaccine dose in participants from its original clinical trial. The companies will offer booster shots to up to 144 participants six to 12 months after they received their second dose of the vaccine. The Phase 1 trial kicked off in May 2020, so some people who participated are already eligible for their third doses.

Pfizer is testing out a 3rd booster shot to bolster its COVID-19 vaccine against new variants

Teladoc

Moderna, Teladoc Health, and Fulgent Genetics have all spiked a lot higher because of COVID-19. And all three companies have platforms for growth over the next decade.

3 Top Healthcare Stocks to Buy in 2021

News for Pfizer Stock (PFE)